Related Experiment Video
Updated: Jul 18, 2025
08:50
Scalable Biomanufacturing Workflow to Produce and Isolate Natural Killer Cell-Derived Extracellular Vesicle-Based Cancer Biotherapeutics
Published on: August 16, 2024
762
Development of Blueberry-Derived Extracellular Nanovesicles for Immunomodulatory Therapy
Tuong Ngoc-Gia Nguyen1, Cuong Viet Pham1, Rocky Chowdhury1
1School of Medicine, Faculty of Health, Deakin University, Geelong Waurn Ponds Campus, Geelong, VIC 3216, Australia.
Pharmaceutics
|August 26, 2023
Summary
Researchers developed a new method to isolate plant extracellular vesicles (EVs) from blueberries. These blueberry EVs show potential as edible nano-platforms for drug delivery and immunomodulatory therapies.
Area of Science:
- Biotechnology
- Nanomedicine
- Plant Science
Background:
- Plant-derived extracellular vesicles (EVs) show promise for precision therapy.
- Current methods for isolating and characterizing plant EVs are insufficient, hindering research progress.
Purpose of the Study:
- To develop an effective method for isolating and characterizing plant EVs.
- To explore the potential of blueberry-derived EVs (BENVs) as a drug delivery system and for immunomodulatory therapies.
Main Methods:
- A novel 3D inner filter-based method was developed for extracting apoplastic fluid (AF) from blueberries.
- Blueberry EVs (BENVs) were isolated and characterized.
- Class I chitinase (PR-3) was identified as a potential universal marker for plant EVs.
Main Results:
- The 3D inner filter method successfully facilitated EV isolation and downstream applications.
- Class I chitinase was identified in BENVs, suggesting its utility as a universal marker.
- BENVs demonstrated high drug loading capacity and the ability to modulate IL-8 and glutathione release under oxidative stress.
Conclusions:
- BENVs represent a promising, edible, multifunctional nano-bio-platform.
- This platform holds potential for future immunomodulatory therapies and advanced drug delivery systems.
